Antibody Start-Ups: Riding the Big Pharma Acquisition Wave

It's a good time to be an antibody company. As almost all the Big Pharma fall over each other to grab whatever antibody assets they can, investors backing still-independent firms are rubbing their hands in glee. One of the companies we profile this month claims it has found a novel route around the one major drawback to antibody development--the dreaded IP blackout. But whatever their trump card-whether they're improving existing antibodies, like Anaptys and 4-antibody, or, like f-star, creating antibody fragments, interest from strategic partners is guaranteed.

It’s a good time to be an antibody company. As almost all the Big Pharmas fall over each other to grab whatever antibody assets they can—at whatever price—investors backing the remaining still-independent antibody companies are rubbing their hands in glee. ( See "Big Pharma’s Leap into Biologics: Bridging both Scientific and Cultural Gaps," IN VIVO , October 2007 Also see "Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps" - In Vivo, 1 October, 2007..)

Many VCs, such as those behind GlycArt, Haptogen, or Adnexus Therapeutics Inc., for instance (acquired by Roche, Wyeth, and Bristol...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.